Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells

Oncogene

Volumn 23, Issue 19, 2004, Pages 3350-3360

  Bao, Bo Ying ^a,b   Hu, Yueh Chiang ^c   Ting, Huei Ju ^a   Lee, Yi Fen ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b University of Rochester   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Androgen; Androgen receptor; Prostate cancer; Vitamin D

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CALCITRIOL; CYCLIN D; CYCLIN DEPENDENT KINASE; PHOSPHOTRANSFERASE; RNA; VITAMIN D;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENZYME ACTIVITY; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANDROGENS; ANILIDES; CALCITRIOL; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CALCITRIOL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 2442716352     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207461     Document Type: Article

References (44)

1. Bikle DD. (1992). Endocr. Rev., 13, 765-784.
2. Blutt SE, Allegretto EA, Pike JW and Weigel NL. (1997). Endocrinology, 138, 1491-1497.
3. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI and Oyasu R. (2001). Prostate, 47, 66-75.
4. Chu YW, Wang R, Schmid I and Sakamoto KM. (1999). Cytometry, 36, 333-339.
5. Darwish H and DeLuca HF. (1993). Crit. Rev. Eukaryot. Gene Expr., 3, 89-116.
6. Esquenet M, Swinnen JV, Heyns W and Verhoeven G. (1996). Prostate, 28, 182-194.
7. Hanchette CL and Schwartz GG. (1992). Cancer, 70, 2861-2869.
8. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE and Jurutka PW. (1998). J. Bone Miner. Res., 13, 325-349.
9. Hedlund TE, Moffatt KA and Miller GJ. (1996). J. Steroid Biochem. Mol. Biol., 58, 277-288.
10. Henttu P, Liao SS and Vihko P. (1992). Endocrinology, 130, 766-772.
11. Hofman K, Swinnen JV, Verhoeven G and Heyns W. (2001). Biochem. Biophys. Res. Commun., 283, 97-101.
12. Inoue T, Kamiyama J and Sakai T. (1999). J. Biol. Chem., 274, 32309-32317.
13. Jones G, Strugnell SA and DeLuca HF. (1998). Physiol. Rev., 78, 1193-1231.
14. Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM. (1992). Nature, 358, 771-774.
15. Knudsen KE, Arden KC and Cavenee WK. (1998). J. Biol. Chem., 273, 20213-20222.
16. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF and Lin MF. (2003). Oncogene, 22, 781-796.
17. Liao J, Ozono K, Sone T, McDonnell DP and Pike JW. (1990). Proc. Natl. Acad. Sci. USA, 87, 9751-9755.
18. Liu M, Lee MH, Cohen M, Bommakanti M and Freedman LP. (1996). Genes Dev., 10, 142-153.
19. Lu S, Jenster G and Epner DE. (2000). Mol. Endocrinol., 14, 753-760.
20. Lu S, Liu M, Epner DE, Tsai SY and Tsai MJ. (1999). Mol. Endocrinol., 13, 376-384.
21. MacDonald PN, Dowd DR and Haussler MR. (1994). Semin. Nephrol., 14, 101-118.
22. MacDonald PN, Dowd DR, Nakajima S, Galligan MA, Reeder MC, Haussler CA, Ozato K and Haussler MR. (1993). Mol. Cell. Biol., 13, 5907-5917.
23. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE and Upadhya P. (1992). Cancer Res., 52, 515-520.
24. Miller GJ, Stapleton GE, Hedlund TE and Moffat KA. (1995). Clin. Cancer Res., 1, 997-1003.
25. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M and Koeffler HP. (1996). Blood, 88, 2201-2209.
26. Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP and Ikeda Y. (1999). Blood, 93, 2225-2233.
27. Myers RB, Oelschlager D, Manne U, Coan PN, Weiss H and Grizzle WE. (1999). Int. J. Cancer, 82, 424-429.
28. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA and Feldman D. (1994). Cancer Res., 54, 805-810.
29. Pols HA, Birkenhager JC, Foekens JA and van Leeuwen JP. (1990). J. Steroid Biochem. Mol. Biol., 37, 873-876.
30. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A. (1994). Genes Dev., 8, 9-22.
31. Schwartz GG and Hulka BS. (1990). Anticancer Res., 10, 1307-1311.
32. Schwartz GG, Oeler TA, Uskokovic MR and Bahnson RR. (1994). Anticancer Res., 14, 1077-1081.
33. Skowronski RJ, Peehl DM and Feldman D. (1993). Endocrinology, 132, 1952-1960.
34. Sui G, Soohoo C, Affar el B, Gay F, Shi Y and Forrester WC. (2002). Proc. Natl. Acad. Sci. USA, 99, 5515-5520.
35. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L and Slingerland J. (2000). Oncogene, 19, 670-679.
36. Yang ES, Maiorino CA, Roos BA, Knight SR and Burnstein KL. (2002). Mol. Cell. Endocrinol., 186, 69-79.
37. Yeh S and Chang C. (1996). Proc. Natl. Acad. Sci. USA, 93, 5517-5521.
38. Yeh S, Hu YC, Wang PH, Xie C, Xu Q, Tsai MY, Dong Z, Wang RS, Lee TH and Chang C. (2003). J. Exp. Med., 198, 1899-1908.
39. Zhao XY, Ly LH, Peehl DM and Feldman D. (1997). Endocrinology, 138, 3290-3298.
40. Zhao XY, Ly LH, Peehl DM and Feldman D. (1999). Endocrinology, 140, 1205-1212.
41. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D. (2000a). Nat. Med., 6, 703-706.
42. Zhao XY, Peehl DM, Navone NM and Feldman D. (2000b). Endocrinology, 141, 2548-2556.
43. Zhuang SH and Burnstein KL. (1998). Endocrinology, 139, 1197-1207.
44. Zhuang SH, Schwartz GG, Cameron D and Burnstein KL. (1997). Mol. Cell. Endocrinol., 126, 83-90.